Pegcetacoplan-Empaveli’s product name and brand introduction

Pegcetacoplan is a new oral complement C3 inhibitor with the trade name Empaveli. It is developed by global pharmaceutical companies and is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and C3 nephropathy/immune complex membranous glomerulonephritis (C3G/IC-MPGN). By inhibiting the activation of C3 complement, this drug reduces the destruction of red blood cells and the inflammatory response caused by immune complexes, thereby improving the symptoms of hemolysis and delaying the progression of kidney damage. It is an important breakthrough in the field of complement inhibition therapy in the world.

PegTak is administered by subcutaneous injection twice weekly, with the dose adjusted based on indication and patient weight. PNH and adult C3G/IC-MPGN patients usually take 1080mg each time, while pediatric patients are stratified in dosage based on body weight to ensure that the blood concentration is within a safe and effective range. Overseas clinical practice shows that this dosage design can inhibit hemolysis and improve the lifespan of red blood cells while reducing potential adverse reactions, embodying the concept of precision medicine. The convenience of subcutaneous injection of the drug in a home environment also provides a feasible solution for long-term management.

BrandEmpaveli has been approved in the international market and has gradually entered the clinical use catalog in many countries. As a representative of C3 complement inhibitors, PEGATAC has demonstrated the potential to sustainably control disease activity and improve hematological indicators and renal function in the treatment of PNH and C3G/IC-MPGN. Patients must fully understand the drug's mechanism of action, dosage regimen, and possible adverse reactions before use, and conduct long-term management under the guidance of a doctor. The launch of PegTac not only provides innovative treatment options for patients with rare blood and kidney diseases, but also marks an important progress in the clinical practice of complement-targeted therapy.

Reference materials:https://empaveli.com/